Niklason Laura E

SEC source: 0001104659-26-073615 · tm2617880-8_4seq1.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

SEC source: 0001628280-25-052715 · wk-form4_1763419703.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,100

Underlying: Common Stock · 311,100 shares

Expires 2035-11-16

F1 · derivative.exercise_date: The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.

SEC source: 0001104659-25-081008 · tm2524042-1_4seq1.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 0

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.53 to $1.69. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-25-081008 · tm2524042-1_4seq1.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 591,685

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.57 to $1.76. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-25-081008 · tm2524042-1_4seq1.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 1,691,685

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.79 to $1.92. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-25-000113 · wk-form4_1750105897.xml · derivative · entry 5

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 0

Underlying: Common Stock · 80,000 shares

Expires 2035-06-12

F2 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.

SEC source: 0001818382-25-000017 · wk-form4_1737668058.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,130,311

Underlying: Common Stock · 1,130,311 shares

Expires 2035-01-21

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.

SEC source: 0001818382-24-000231 · wk-form4_1734732576.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F1 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-24-000208 · wk-form4_1732147588.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 1,730,884

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000208 · wk-form4_1732147588.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 1,992,253

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000214 · wk-form4_1732192270.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,851

F1 · shares: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase.

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000208 · wk-form4_1732147588.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 2,419,712

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000184 · wk-form4_1726091430.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,230,884

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.14 to $5.325. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000184 · wk-form4_1726091430.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,519,558

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.36 to $5.505. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000166 · wk-form4_1724971594.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 3,677,262

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000177 · wk-form4_1725395025.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,054

F1 · shares: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $3,391.05, representing the full amount of profit realized in connection with this purchase.

SEC source: 0001818382-24-000166 · wk-form4_1724971594.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,029,374

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000166 · wk-form4_1724971594.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,306,464

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000138 · wk-form4_1718655122.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000101 · wk-form4_1718311705.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,559,140

F2 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.545. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000101 · wk-form4_1718311705.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,830,658

F2 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.00 to $7.115. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000101 · wk-form4_1718311705.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,907,288

F1 · shares: Shares were sold in a private transaction to a trust controlled by family members of the Reporting Person. Said family members do not share the same household as the Reporting Person.

SEC source: 0001818382-24-000087 · wk-form4_1717542316.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,832

F1 · shares: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 93,213 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $7,015.79, representing the full amount of profit realized in connection with this purchase.

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.3497 to $6.3499. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 4

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,189,288

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F6 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.265 to $7.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000076 · wk-form4_1717446687.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,470

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,191,140

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F5 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.625. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,381,354

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · shares: A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Dr. Niklason of 2,050 shares of the Issuer's common stock on June 3, 2024, at a price per share of $7.37. The Reporting Person has paid the Issuer $4,007.76, representing the full amount of profit realized in connection with this sale.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.41 to $9.345. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,474,567

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.405 to $8.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-23-000191 · wk-form4_1702415348.xml · derivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,100

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F2 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-23-000191 · wk-form4_1702415348.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 803,000

Underlying: Common Stock · 803,000 shares

Expires 2033-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.

SEC source: 0001818382-23-000153 · wk-form4_1696968477.xml · derivative · entry 4

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,176

Underlying: Common Stock · 114,420 shares

Expires 2023-11-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-23-000153 · wk-form4_1696968477.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,384,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-23-000130 · wf-form4_169480836158057.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 6,191,140

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

SEC source: 0001818382-23-000121 · wf-form4_169265565726867.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 8,191,140

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-23-000121 · wf-form4_169265565726867.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 8,793,583

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-23-000121 · wf-form4_169265565726867.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 9,420,562

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-23-000084 · wf-form4_168694616392845.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 15, 2024, after which 1/48 of the option will become exercisable on the 15th of each month through June 15, 2027.

SEC source: 0001818382-23-000083 · wf-form4_168694588567524.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 9,990,736

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

SEC source: 0001818382-23-000049 · wf-form4_168686046417140.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 10,490,736

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

SEC source: 0001104659-23-065546 · tm2317123-9_4seq1.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 15,365,736

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

SEC source: 0001818382-23-000003 · wf-form4_167779102542302.xml · derivative · entry 4

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,596

Underlying: Common Stock · 100,000 shares

Expires 2023-11-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-23-000003 · wf-form4_167779102542302.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,270,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-22-000221 · wf-form4_167149938921327.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 17,990,736

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.50 to $2.63. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-22-000211 · wf-form4_167115188797248.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 18,230,274

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-22-000223 · wf-form4_167149963704147.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,170,240

F1 · shares: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase.

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-22-000211 · wf-form4_167115188797248.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 18,323,700

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.75 to $2.87. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-22-000211 · wf-form4_167115188797248.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 18,600,004

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-22-000197 · wf-form4_167087945823074.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 444,500

Underlying: Common Stock · 444,500 shares

Expires 2032-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026.

SEC source: 0001818382-22-000167 · wf-form4_166362046815607.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,160,240

SEC source: 0001818382-22-000161 · wf-form4_166361976999359.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 18,930,004

F1 · shares: This sale was made by an entity controlled by the spouse of Laura Niklason, the Reporting Person. This sale was done as a block trade to an existing investor of Humacyte, Inc. Laura Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Laura Niklason were sold in this transaction.